Last reviewed · How we verify
NCT04122911: TENEC
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Completed
Phase 2
Last updated 26 October 2020
What this trial tests
Phase 2 trial testing Temozolomide in Neuroendocrine Carcinomas in 25 participants. Completed in 16 December 2019.
Timeline
29 January 2017
Primary endpoint
30 December 2017
30 December 2017
16 December 2019
Quick facts
| Lead sponsor | National Cancer Institute, Naples |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 29 January 2017 |
| Primary completion | 30 December 2017 |
| Estimated completion | 16 December 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Temozolomide (temozolomide) — full drug profile →
Conditions studied
- Neuroendocrine Carcinomas — all drugs for Neuroendocrine Carcinomas →
Sponsor
National Cancer Institute, Naples
Who can join
18 and older, any sex, with Neuroendocrine Carcinomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
Frizziero M, Kilgour E, Simpson KL, Rothwell DG, et al · · 2022 · cited 30× · PMID 35091446 · DOI 10.1158/1078-0432.ccr-21-3058 -
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma.
Weaver JMJ, Hubner RA, Valle JW, McNamara MG. · · 2023 · cited 8× · PMID 37894318 · DOI 10.3390/cancers15204951 -
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.
Robinson MD, Livesey D, Hubner RA, Valle JW, et al · · 2023 · cited 8× · PMID 36872945 · DOI 10.1177/17588359231156870 -
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
von Arx C, Della Vittoria Scarpati G, Cannella L, Clemente O, et al · · 2024 · cited 4× · PMID 38615472 · DOI 10.1016/j.esmoop.2024.103003 -
Progress in the treatment of esophageal neuroendocrine carcinoma (Review).
Shi J, He B, Zhang HD, Jiang CY, et al · · 2026 · cited 1× · PMID 41235358 · DOI 10.3892/ol.2025.15367
Verify or expand the search:
- PubMed search for NCT04122911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Temozolomide
Trials testing the same drug.
- NCT04373785 — NG101m Adjuvant Therapy in Glioblastoma Patients · Phase 1, PHASE2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
- NCT07452458 — Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, ID · Phase 3 · not yet recruiting
- NCT06639607 — PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/Hi · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Neuroendocrine Carcinomas
Currently open trials in the same condition.
- NCT06041516 — A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant · Phase 1 · recruiting
Other National Cancer Institute, Naples trials
Trials by the same sponsor.
- NCT07459920 — Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden · Phase 2 · not yet recruiting
- NCT07302451 — REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) · Phase 2 · active not recruiting
- NCT06714357 — ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer · Phase 2 · recruiting
- NCT06886282 — Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease · recruiting
- NCT06887244 — Effectiveness of Nurse Tele-consultation on the Quality of Elective Colonoscopy, Procedure-related Anxiety, and Financia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04122911 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Naples
- Last refreshed: 26 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing